satumomab pendetide
Trade name: Oncoscint
mAbapprovedADCImaging agentOrphan Drug FDA
Approved
Jun 1, 1998
Indium (111In) satumomab pendetide is a mouse monoclonal antibody which is used for cancer diagnosis. The antibody, satumomab, is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Mechanism of action
- Tumor antigensBINDING AGENT
Tumor antigens binding agent
Approval history
- approvedJun 1, 1998
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Multi-specific
- No
- Imaging
- 111-Indium
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIndium (111In) satumomab pendetide ↗
- ChEMBLCHEMBL1743091 ↗
Also known as
- 111in-cyt-103
- b72.3
- b72.3
- b72.3 antibody
- b72.3-glycyl-tyrosyl n-diethylenetriaminepentacetic acid
- b72.3-gyk-dtpa
- cyt-099
- cyt 103
- cyt-103
- cyt-103 (111in)
- indium (111in) satumomab pendetide
- indium (111in) satumomab pendetide
- indium 111in-satumomab pendetide
- indium-111 satumomab pendetide
- indium-111 satumomab pendetide
- indium in 111 cyt-103
- indium in 111 satumomab pendetide
- indium in 111 satumomab pendetide
- indium in-111 satumomab pendetide
- monab b72.3-gyk-dtpa-111in
- oncoscint
- oncoscint
- oncoscint
- oncoscint cr103
- oncoscint cr/ov
- satumomab
- satumomab pendetide
- satumomab pendetide 111in
Organizations
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Cytogen | For profit | NDA | Dec 31, 1992 |